Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma;…
| Periodo | 2026-11 | 2022-04 | 2021-04 |
|---|---|---|---|
| Real | — | $-0.16 | $-0.18 |
| Estimado | $-0.15 | $-0.17 | $0.05 |
| Sorpresa | — | +5.9% | -460.0% |
| Métrica | IPHA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -599.8% | -34.4% | -565.4% |
| Net Margin | -546.1% | -32.5% | -513.7% |
| FCF Margin | -587.4% | -12.6% | -574.8% |
| ROE | — | -39.2% | — |
| ROA | -78.4% | -30.9% | -47.5% |
| Current Ratio | 1.27 | 2.73 | -1.46 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -78.4% | — |
| ✗Flujo de caja operativo positivo | −€53M | −€7M |
| ✗Rentabilidad sobre activos al alza | -78.4% | -44.5% |
| ✗Caja operativa/activos supera al ROA | -84.1% | ROA -78.4% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.27 | 2.60 |
| ✗Sin aumentar el nº de acciones | 89M | 81M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | 0.14 | 0.18 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -587.4% |
| ✗ROCE > 10 % | -207.2% |
| ✗Ventas > 5 %/año (3 años) | -46.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 486.0% |
Innate Pharma SA cotiza a 1.43 USD y tiene una capitalización bursátil de $160M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud